Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag

Abstract Introduction Patients with connective tissue disorders (CTD) and pulmonary arterial hypertension (PAH) have a poorer prognosis than those with other PAH etiologies. This study assessed the impact of CTD on healthcare outcomes among PAH patients with and without CTD comorbidities that were t...

Full description

Bibliographic Details
Published in:	Rheumatology and Therapy
Main Authors:	Yuen Tsang, Risho Singh, Sumit Verma, Sumeet Panjabi
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-03-01
Subjects:	Pulmonary arterial hypertension Selexipag Connective tissue disease Health care costs
Online Access:	https://doi.org/10.1007/s40744-023-00547-z

Similar Items

Selexipag in pregnancy and pulmonary arterial hypertension
by: Sweta Mohanty, et al.
Published: (2023-01-01)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
by: Hardin EA, et al.
Published: (2016-11-01)

Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study
by: Yuen Tsang, et al.
Published: (2023-12-01)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
by: Elizabeth Colglazier, et al.
Published: (2022-10-01)

Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
by: Richard Channick, MD, et al.
Published: (2025-02-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023-03-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023-08-01)

Efficacy and Safety of Selexipag Treatment in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease
by: Chebly Dagher, et al.
Published: (2025-06-01)

CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
by: Z. S. Valieva, et al.
Published: (2019-12-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01)

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients
by: Xiaopei Cui, et al.
Published: (2022-09-01)

Retrospective evaluation of Selexipag monotherapy on pulmonary hemodynamics in newly diagnosed, treatment-naïve patients with chronic thromboembolic pulmonary hypertension prior to balloon pulmonary angioplasty
by: Naohiro Komura, et al.
Published: (2026-08-01)

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
by: Ayako Chida-Nagai, et al.
Published: (2022-06-01)

The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
by: Akram Khan, et al.
Published: (2023-01-01)

Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study)
by: Yuichi Tamura, et al.
Published: (2024-04-01)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
by: André Alexandre, et al.
Published: (2023-08-01)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
by: Mizuki Momoi, et al.
Published: (2022-01-01)

Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
by: E. A. Rezukhina, et al.
Published: (2023-03-01)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
by: Wenxing Dong, et al.
Published: (2023-08-01)

Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review
by: Burger CD, et al.
Published: (2024-05-01)

New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
by: N. V. Ilyin, et al.
Published: (2019-12-01)

Assessment of the effectiveness of PAH-specific therapy, including selexipag, in patients with idiopathic pulmonary hypertension according to a comprehensive examination using Raman spectroscopy
by: E. S. Allakhverdiev, et al.
Published: (2023-11-01)

Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)
by: Alberto Jiménez, et al.
Published: (2018-12-01)

Possibility of evaluation of oxygen transport function in PAH patients on effective selexipag-based therapy
by: E. S. Allakhverdiev, et al.
Published: (2023-10-01)

Stability indicating LC-MS/MS method and validation of Selexipag impurities and identification of its force degradation products
by: Pranavkumar Shah, et al.
Published: (2023-12-01)

PULMONARY ARTERIAL HYPERTENSION: REGIONAL HEALTH CARE OPPORTUNITIES
by: E. V. Filippov
Published: (2021-05-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01)

Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag
by: Stacy Davis, et al.
Published: (2023-12-01)

Direct prostacyclin transition in pediatric patients with pulmonary hypertension
by: Kelly Merrill, et al.
Published: (2024-04-01)

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis
by: Khaled M. Saleh, et al.
Published: (2025-10-01)

Pulmonary arterial hypertension: challenges and achievements 2021
by: E. A. Rezukhina, et al.
Published: (2022-03-01)

Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report
by: S. A. Musashaykhova, et al.
Published: (2022-12-01)

Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension
by: Charles D. Burger, et al.
Published: (2024-07-01)

The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review
by: Goren S, et al.
Published: (2025-01-01)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
by: Asuka Furukawa, et al.
Published: (2017-10-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
by: Aparna C. Swaminathan, et al.
Published: (2024-11-01)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
by: Yuichi Tamura, et al.
Published: (2022-01-01)

PULMONARY ARTERIAL HYPERTENSION IN CONNECTIVE TISSUE DISEASES
by: A. V. Volkov
Published: (2015-03-01)

Connective tissue disease‐associated pulmonary hypertension: A comprehensive review
by: Vikramjit Khangoora, et al.
Published: (2023-10-01)

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)
by: Yuen Tsang, et al.
Published: (2023-04-01)